



# Marathon Patent Group Announces United States Patent and Trademark Office to Close '375 Patent Reexamination

## Finds Claims 1 and 7 Patentable

LOS ANGELES, CA -- (Marketwired) -- 06/23/15 -- **Marathon Patent Group, Inc.** (NASDAQ: MARA) ("Marathon"), a patent licensing company, announced that on June 18, 2015 the Company received notice from the United States Patent and Trademark Office (USPTO) that it is closing the ex-parte reexamination filed 10/27/2014 on its US5732375 ('375) patent, requested for claims 1 and 7 along with any other relevant claims.

The Office action closes prosecution in the ex-parte reexamination of the '375 patent. Claims 1 and 7 were subject to reexamination and are confirmed. The Company anticipates a re-examination certificate to issue shortly.

"We are pleased to have received notice from the USPTO that they are closing the ex-parte reexamination of the '375 patent, finding claims 1 and 7 patentable. Generally speaking, the successful emergence from the reexamination process itself results in a strengthening of the asset by reducing the likelihood of a future finding of invalidity. This is another tangible result that shows the value of our model of only acquiring the highest quality assets capable of holding up to challenge," said Doug Croxall, CEO of Marathon Patent Group.

## **About Marathon Patent Group**

Marathon is a patent acquisition and monetization company. The Company acquires patents from a wide-range of patent holders from individual inventors to Fortune 500 companies. Marathon's strategy of acquiring patents that cover a wide-range of subject matter allows the Company to achieve diversity within its patent asset portfolio. Marathon generates revenue with its diversified portfolio through actively managed concurrent patent rights enforcement campaigns. This approach is expected to result in a long-term, diversified revenue stream. To learn more about Marathon Patent Group, visit [www.marathonpg.com](http://www.marathonpg.com).

## **Safe Harbor Statement**

Certain statements in this press release constitute "forward-looking statements" within the meaning of the federal securities laws. Words such as "may," "might," "will," "should," "believe," "expect," "anticipate," "estimate," "continue," "predict," "forecast," "project," "plan," "intend" or similar expressions, or statements regarding intent, belief, or current expectations, are forward-looking statements. While the Company believes these forward-looking statements are reasonable, undue reliance should not be placed on any such forward-looking statements, which are based on information available to us on the date of this release. These forward looking statements are based upon current estimates and assumptions and are subject to various risks and uncertainties, including without limitation

those set forth in the Company's filings with the Securities and Exchange Commission (the "SEC"), not limited to Risk Factors relating to its patent business contained therein. Thus, actual results could be materially different. The Company expressly disclaims any obligation to update or alter statements whether as a result of new information, future events or otherwise, except as required by law.

***CONTACT INFORMATION***

Marathon Patent Group

Jason Assad

678-570-6791

[Jason@marathonpg.com](mailto:Jason@marathonpg.com)

Source: Marathon Patent Group